Bayer chief eyes $2.6B in Xarelto sales

Bayer CEO Werner Wenning predicted that the market for new blood thinners could reach $12 billion to $15 billion, with his company's drug Xarelto--now awaiting U.S. approval--accounting for some $2.6 billion of that. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.